Molecular Analysis Identifies A Subset Of Non-small Cell Lung Cancer Patients With Differential Sensitivity To Histone Deacetylase Inhibitor (hdaci)/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (egfr-tki) Treatment

被引：0

作者：

Jotte, R. M. ^{[1
]}

Witta, S. E. ^{[2
]}

Spira, A. I. ^{[3
]}

Neubauer, M. A. ^{[4
]}

Konduri, K. ^{[5
]}

Ruxer, R. L. ^{[6
]}

Hirsch, F. R. ^{[7
]}

机构：

[1] Rocky Mt Canc Ctr, Denver, CO USA

[2] Mt Blue Canc Care Ctr, Wheat Ridge, CO USA

[3] Virginia Canc Specialists, INOVA Thorac Oncol Program, Fairfax, VA USA

[4] Kansas City Canc Ctr, Overland Pk, KS USA

[5] Baylor Sammons Canc Ctr, Dallas, TX USA

[6] SW Ft Worth Canc Ctr, Ft Worth, TX USA

[7] Univ Colorado, Ctr Canc, Aurora, CO USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S559 / S560

页数：2

共 50 条

[21] ACTIVATION OF CYTOMEGALOVIRUS IN A PATIENT ON EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR TREATMENT IN NON-SMALL CELL LUNG CANCER
Dawes, Sean M.
Plichta, Christine
Gaddipati, Himaja
Hamade, Sam
Biedny, Adam
de Villate, Oscar F. Parodi Ortiz
CHEST, 2023, 164 (04) : 972A - 973A
[22] Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
Lee, Sanghun
Joo, Jeonghyun
Kwak, Minah
Sohn, Kicheul
Chon, Songha
ONCOTARGETS AND THERAPY, 2018, 11 : 3943 - 3947
[23] Cytokeratin 19 fragment (CYFRA21-1) to predict the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) harboring EGFR mutation
Tanaka, Kosuke
Hata, Akito
Kaji, Reiko
Fujita, Shiro
Takeshita, Jumpei
Matsumoto, Takeshi
Monden, Kazuya
Nagata, Kazuma
Otsuka, Kyoko
Nanjo, Shigeki
Tachikawa, Ryo
Otsuka, Kojiro
Hayashi, Michio
Tomii, Keisuke
Katakami, Nobuyuki
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[24] Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer
Yang, Guangdie
Yao, Yinan
Zhou, Jianya
Zhao, Qiong
ONCOLOGY REPORTS, 2012, 27 (06) : 2066 - 2072
[25] THE ROLE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
Mok, Tony
ANNALS OF ONCOLOGY, 2010, 21 : 5 - 5
[26] Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer
Martin-Fernandez, Marisa L.
CANCERS, 2022, 14 (03)
[27] Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Lee, Jae Cheol
Jang, Seung Hun
Lee, Kye Young
Kim, Young-Chul
CANCER RESEARCH AND TREATMENT, 2013, 45 (02): : 79 - 85
[28] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
Gadgeel, Shirish M.
Ruckdeschel, John C.
Heath, Elisabeth I.
Heilbrun, Lance K.
Venkatramanamoorthy, Raghu
Wozniak, Antoinette
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 299 - 305
[29] A meta-analysis of the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
Xu, Hongmei
Minchella, Kaitlyn
Zhou, Diansong
Al-Huniti, Nidal
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[30] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Non-Small Cell Lung Cancer With Uncommon Mutations
Kanazu, Masaki
Naoki, Yoko
Shiroyama, Takayuki
Tamiya, Motohiro
Tamiya, Akihiro
Omachi, Naoki
Okishio, Kyoichi
Suzuki, Hidekazu
Okamoto, Norio
Morishita, Naoko
Hirashima, Tomonori
Atagi, Shinji
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S318 - S318

← 1 2 3 4 5 →